XFOR is in the HouseSee the comments on the chart; I intentionally left my chart clean as I see this as a great stock for a training session.
If you are interested, leave a note in the comments.
As always, enjoy every sandwich with a great drink ;)
−1.0464USD
−93.867MUSD
124.65M
About X4 Pharmaceuticals, Inc.
Sector
Industry
CEO
Paula S. Ragan
Website
Headquarters
Boston
Employees (FY)
70
Founded
2010
ISIN
US98420X1037
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
XFOR - 140% UPSIDE- Triangle breakout
- buy pullbacks dips
- Tipranks Analyst rating $22 median price target
- The FDA has designated Rare Pediatric Disease status to X4 Pharmaceuticals (XFOR -2.4%) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathex
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
